Protective encapsulating devices and gene-editing technologies could obviate the need for antirejection drugs in stem-cell-derived therapies for diabetes.
This is a preview of subscription content, log in via an institution to check access.
Kadimastem
Change history
22 April 2022
A Correction to this paper has been published: https://doi.org/10.1038/s41587-022-01322-1
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dolgin, E. Diabetes cell therapies take evasive action. Nat Biotechnol 40, 291–295 (2022). https://doi.org/10.1038/s41587-022-01246-w
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-022-01246-w
- Springer Nature America, Inc.
This article is cited by
-
Inflammation-induced subcutaneous neovascularization for the long-term survival of encapsulated islets without immunosuppression
Nature Biomedical Engineering (2023)
-
Challenges with Cell-based Therapies for Type 1 Diabetes Mellitus
Stem Cell Reviews and Reports (2023)
-
Engineering the next generation of cell-based therapeutics
Nature Reviews Drug Discovery (2022)